Kiki Patel
Head of Investor Relations
Replay available
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call
Vir Biotechnology, Inc. (NASDAQ: VIR) Q1 2026 earnings conference call, held 2026-05-06. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Marianne DeBacher
Chief Executive Officer
Jason O'Byrne
Chief Financial Officer
Paul Choi
Analyst, Goldman Sachs
Phil Natto
Analyst, TD Cowen
Sean McCutcheon
Analyst, Raymond James
Joseph Stringer
Analyst, Needham
Luis Santos
Analyst for H.C. Wainwright (Patrick Trucchio)
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Vir Biotechnology, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.689 -- 00:00:05.774 Hello, and welcome to Veer Biotechnology's first quarter 2026 00:00:05.774 -- 00:00:09.257 financial results and corporate update conference call. 00:00:09.257 -- 00:00:12.220 As a reminder, this call is being recorded. 00:00:12.220 -- 00:00:15.924 At this time, all participants are in a listen-only mode. 00:00:15.924 -- 00:00:20.028 After the speaker's presentation, there will be a question and answer session. 00:00:20.028 -- 00:00:24.212 I will now turn the call over to Kiki Patel, Head of Investor Relations. 00:00:24.212 -- 00:00:26.835 You may begin, Kiki. 00:00:26.835 -- 00:00:29.900 Thank you, Operator, and welcome, everyone. 00:00:29.900 -- 00:00:35.269 Earlier today, we issued a press release reporting our first quarter 2026 00:00:35.269 -- 00:00:38.797 financial results and corporate update. 00:00:39.198 -- 00:00:43.464 Before we begin, I would like to remind everyone that some of the statements we are making 00:00:43.464 -- 00:00:47.850 today are forward-looking statements under applicable securities laws. 00:00:47.850 -- 00:00:52.176 These forward-looking statements involve substantial risks and uncertainties that could 00:00:52.176 -- 00:00:57.924 cause our clinical development programs, collaboration outcomes, future results, performance 00:00:57.924 -- 00:01:03.352 or achievements to differ significantly from those expressed or implied by such forward-looking 00:01:03.352 -- 00:01:04.949 statements. 00:01:04.949 -- 00:01:09.300 Forward-looking statements include, but are not limited to, statements regarding the 00:01:09.300 -- 00:01:15.054 potential benefits of our collaboration with Astellas, the therapeutic potential of 00:01:15.054 -- 00:01:20.106 VEER 5500 and our Pro X STEM platform, our development plans and tim...